Media coverage about Oncomed Pharmaceuticals (NASDAQ:OMED) has been trending somewhat positive on Sunday, according to Accern Sentiment Analysis. The research firm scores the sentiment of media coverage by monitoring more than 20 million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oncomed Pharmaceuticals earned a daily sentiment score of 0.17 on Accern’s scale. Accern also gave headlines about the biopharmaceutical company an impact score of 48.7758567155289 out of 100, indicating that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.
Several equities analysts recently weighed in on OMED shares. Zacks Investment Research raised shares of Oncomed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Tuesday, July 17th. ValuEngine raised shares of Oncomed Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, June 2nd. Five analysts have rated the stock with a hold rating and one has given a buy rating to the company. Oncomed Pharmaceuticals presently has a consensus rating of “Hold” and an average target price of $4.30.
Oncomed Pharmaceuticals traded up $0.02, hitting $2.42, during trading on Friday, according to Marketbeat.com. 29,683 shares of the company traded hands, compared to its average volume of 61,719. The stock has a market capitalization of $92.40 million, a price-to-earnings ratio of -2.33 and a beta of 1.78. Oncomed Pharmaceuticals has a 1 year low of $1.74 and a 1 year high of $5.56.
Oncomed Pharmaceuticals (NASDAQ:OMED) last issued its quarterly earnings data on Thursday, August 2nd. The biopharmaceutical company reported ($0.10) EPS for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.13. The business had revenue of $6.87 million during the quarter, compared to analysts’ expectations of $7.49 million. analysts anticipate that Oncomed Pharmaceuticals will post -0.64 earnings per share for the current year.
Oncomed Pharmaceuticals Company Profile
OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway.
Featured Article: Stock Symbols and CUSIP Explained
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.